Martínez-Ríos MA, Méndez-Ortíz A, Gaspar J, Barragán-García R, Fernández-de-la-Reguera G, González-Quesada CJ

Idioma: Español
Referencias bibliográficas: 20
Paginas: 407-412
Archivo PDF: 158.35 Kb.

RESUMEN

Cardiac transplantation is a well defined therapy for end stage heart failure. After the first year of transplantation, allograft coronary artery disease (ACAD) is the second main cause of death. The ACAD is defined as a diffuse process affecting the entire length of epicardial vessels. Once ACAD has been established, treatments such as coronary angioplasty, coronary stenting, and coronary bypass are performed. We present a case of successful stenting of the left main coronary artery (LMCA) in a patient with ACAD. The patient’s medical history was significant for heart transplantation due to ischemic heart failure. Four years after transplantation the patient was admitted again due to sudden worsening of New York Heart Association functional class and extreme fatigue. Coronary angiogram showed a severe stenosis in the proximal segment of the LMCA; we performed stenting with a paclitaxel-eluting stent (PES). Six months after the procedure, the patient had an elective angiogram, where we discovered a new severe occlusion distally to the former stent; a second PES was implanted. Fourteen months after the second stenting, a new elective angiogram was performed without evidence of in-stent restenosis. After a 8-year follow-up since transplantation, the patient is free from dyspnea, angina, and adverse cardiovascular events. Our report suggests the efficacy of PES as ACAD treatment of the unprotected LMCA.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI: International Society for Heart and Lung Transplantation. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report – 2006. J Heart Lung Transplant 2006 25: 880-892.

2. International Society of Heart and Lung Transplantation (ISHLT) registry. http://www.ishlt.org/registries. [Accessed May 9th, 2007]

3. Avery RK: Cardiac-allograft vasculopathy. N Engl J Med 2003; 349: 829-830.

4. Billingham ME: Histopathology of graft coronary artery disease. J Heart Lung Transplant 1992; 11(3 Pt 2): S38-S44.

5. Miniati DN, Robbins RC: Heart transplantation: a thirty year perspective. Annu Rev Med 2002; 53: 189-205.

6. Lenzen MJ, Boersma E. Bertrand ME, Maier W, Moris C, Piscione F, et al: European Society of Cardiology. Management and outcome of patients with established coronary artery disease: The Euro Heart Survey on coronary revascularization. Eur Heart J 2005; 26: 1169-79.

7. Costanzo MR, Naftel DC, Pritzker MR, Heilman JK 3rd, Boehmer JP, Brozena SC, et al: Heart transplant coronary artery disease detected by coronary angiography: A multi-institutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant 1992; 17: 744-753.

8. Boehmer JP, Brown CV, Leier CV: Advanced allograft coronary artery disease: Interaction between pre- and post-transplant risk factors from a ten-year multi-institutional study (abstract). J Heart Lung Transplant 2002; 21: 19.

9. Keogh A, Valantine H, Hung SA, Schroeder JS, McIntosh N, Over PE, et al: Impact of proximal or mid-vessel discreet coronary artery stenosis on survival after heart transplantation. J Heart Lung Transplant 1992; 11: 892-901.

10. Boffa G, Faggian G, Buja G: Coronary artery spasm in heart transplant recipients. J Heart Lung Transplant 1989; 8: 154-158.

11. St Goar FG, Pinto FJ, Alderman EL, Valantine HA, Schroeder JS, Gao SZ, et al: Intracoronary ultrasound in cardiac transplant recipients: in vivo evidence of ‘angiographically silent’ intimal thickening. Circulation 1992; 85: 979-987.

12. Kapadia SR, Ziada KM, L’Allier PL, Crowe TD, Rincon G, Hobbs RE, et al: Intravascular ultrasound imaging after cardiac transplantation: advantage of multivessel imaging. J Heart Lung Transplant 2000; 19: 167-172.

13. Ramzy D, Rao V, Brahm J, Miriuka S, Delgado D, Ross HJ, et al: Cardiac allograft vasculopathy: a review. Can J Surg 2005; 48: 319-327.

14. Aranda JM, Hill J: Cardiac transplant vasculopathy. Chest 2000; 118: 1792-1800.

15. Eisen HJ, Tuzcu EM, Doren R, Kobashigawa J, Mancini D: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-58.

16. Halle AA III, DiSciascio G, Massin EK, Wilson RF, Johnson MR, Sullivan HJ, et al: Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. JAMA 1995; 26: 120-8.

17. Musci M, Loebe M, Wellnhofer E, Meyer R, Pasic M, Hummel M, et al: Coronary angioplasty, bypass surgery, and retransplantation in cardiac transplant patients with graft coronary disease. Thorac Cardiovasc Surg 1998; 46: 268-74.

18. Schnetzler B, Drobinski G, Dorent R, Camproux AC, Ghossoub J, Thomas D, et al: The role of percutaneous coronary angioplasty in heart transplant recipients. J Heart Lung Transplant 2000; 19: 557-65.

19. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al; RAVEL Study Group Randomized study with the sirolimus-coated bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.

20. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, et al: TAXUS-IV Investigators: A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 1002; 350: 221-31.